Search Within

Lymphoma

Formats
  1. Meeting Abstract (1382)
  2. Journal Article (1050)
  3. Book Section (64)
  4. Review (63)
  5. Editorial (38)
  6. Research Letter (37)
  7. Guidelines (18)
  8. Conference Paper (15)
  9. Correspondence (11)
  10. Miscellaneous (5)
  11. Book Whole (4)
Groups
  1. Center for Hematologic Malignancies (2687)
  2. Department of Medicine (2687)
  3. Hematologic Malignancies, Division of (2687)
  4. Population Sciences Research Program (741)
  5. Survivorship Research (651)
  6. Executive Committee, Center for Hematologic Malignancies (391)

More Groups

People
  1. Andrew Zelenetz (781)
  2. Steven Horwitz (663)
  3. Maria Palomba (440)
  4. Ariela Noy (368)
  5. David Straus (360)
  6. Alison Moskowitz (355)

More People

Years
  1. 2025 (34)
  2. 2024 (141)
  3. 2023 (180)
  4. 2022 (170)
  5. 2021 (171)
  6. 2020 (170)

More Years

Publications
  1. Blood (875)
  2. Journal of Clinical Oncology (275)
  3. Hematological Oncology (110)
  4. Leukemia and Lymphoma (81)
  5. British Journal of Haematology (80)
  6. Haematologica (71)

More Publications

Publishers
  1. American Society of Hematology (940)
  2. American Society of Clinical Oncology (291)
  3. Elsevier Inc. (186)
  4. Wiley Blackwell (174)
  5. John Wiley & Sons (95)
  6. Nature Publishing Group (92)

More Publishers

Results (2687)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Infectious complications in patients with relapsed or refractory (R/R) Non-Hodgkin's lymphoma (NHL) treated with the anti-CD20xCD3 bispecific antibody (BsAb) mosunetuzumab
    Meeting Abstract

    Shahid, Z.; Okwali, M.; Joseph, A.; Seo, S. K.; Lue, J. K.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Cumulative incidence of myeloid neoplasms in patients with nodal T-follicular helper cell lymphoma
    Meeting Abstract

    Stuver, R.; Ganesan, N.; Dogan, A.; Epstein-Peterson, Z. D.; Ghione, P.; Johnson, W.; Lewis, N.; Moskowitz, A.; Shah, G. L.; Scordo, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-world outcomes in patients with transformed follicular lymphoma treated with CD19-targeting CAR-T therapy
    Meeting Abstract

    Rivas-Delgado, A.; Luttwak, E.; Drill, E.; Goldstein, I.; Landego, I.; Tomas, A. A.; Parascondola, A.; Saldia, A.; Caron, P.; Dahi, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of limited stage high grade B-cell lymphoma with MYC/BCL2 and/or BCL6 rearrangements: A single center experience
    Meeting Abstract

    Lue, J. K.; Luttwak, E.; Caron, P.; Boardman, A. P.; David, K. A.; Rivas-Delgado, A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Hamlin, P. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Potent CD8+T-cell proliferation and effector differentiation following subcutaneous (SC) mosunetuzumab administration in patients with untreated, high tumor-burden follicular lymphoma (FL)
    Meeting Abstract

    Falchi, L.; Lin, Y. H.; Melendez, L.; Ghione, P.; Owens, C.; Hamlin, P. A.; Lue, J. K.; Epstein-Peterson, Z. D.; Kumar, A.; Palomba, M. L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Brentuximab vedotin-based regimens for older patients with newly diagnosed classical Hodgkin lymphoma -Real world experience
    Meeting Abstract

    Luttwak, E.; Ganesan, N.; Boardman, A. P.; Caron, P.; David, K. A.; Rivas-Delgado, A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • TITLE: A pilot study of 89Zr-DFO-REGN3767 anti-LAG-3 antibody positron emission tomography in patients with diffuse large B-cell lymphoma
    Meeting Abstract

    Pandit-Taskar, N.; Shutian, R.; Grkovski, M.; Schwartz, J.; Lyashchenko, S.; Cheung, K.; Uldrick, T.; Ma, D.; Giurleo, J.; Palomba, L.
    Journal of Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • Pirtobrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients with prior cBTKi: Safety and efficacy including high-risk subgroup analyses from the phase 1/2 BRUIN study
    Meeting Abstract

    Cohen, J. B.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Cheah, C. Y.; Eyre, T. A.; Ujjani, C. S.; Koh, Y.; Kim, W. S.; Nasta, S. D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed / refractory marginal zone lymphoma: Results from phase 1/2 BRUIN study
    Meeting Abstract

    Patel, K.; Vose, J. M.; Nasta, S. D.; Brown, J. R.; Maddocks, K. J.; Woyach, J. A.; Shah, N. N.; Fakhri, B.; Tessoulin, B.; Ma, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • TRANSCEND FL: Phase 2 study primary analysis of lisocabtagene maraleucel as second-line therapy in patients with high-risk relapsed or refractory follicular lymphoma
    Meeting Abstract

    Morschhauser, F.; Dahiya, S.; Palomba, M. L.; Garcia-Sancho, A. M.; Reguera, J. L.; Kuruvilla, J.; Jaeger, U.; Cartron, G.; Izutsu, K.; Dreyling, M.; more...
    Blood (2023)

    Fulltext@MSK | Save